Postprandial plasma glucose excursion is associated with an atherogenic lipid profile in individuals with type 2 diabetes mellitus: A cross-sectional study

Po-Chung Cheng, Chia-Hung Kao

Graduate Institute of Biomedical Sciences, China Medical University, Taichung City, Taiwan

* 180459@cch.org.tw

Abstract

Coronary heart disease (CHD) is a prevalent complication of type 2 diabetes mellitus (T2DM). The atherogenic low-density lipoprotein (LDL) cholesterol is an established risk factor of cardiovascular disease, and evidence also suggests that postprandial plasma glucose (PPG) levels closely delineate CHD mortality in diabetes. The investigators hypothesized that postprandial plasma glucose excursion (PPGE), defined as the difference between 2-hour PPG and fasting plasma glucose (FPG), may be associated with plasma LDL cholesterol levels in patients with T2DM. This study enrolled diabetic participants for whom FPG and lipid profile were sampled after a 12-hour fast, followed by PPG sampling two hours after consuming a standard meal with 75 grams of carbohydrates. The study enrolled 379 participants who were divided into PPGE tertiles according to the difference between their 2-hour PPG and FPG. Participants in the highest PPGE tertile had considerably greater plasma LDL cholesterol levels than patients in the lowest tertile (126.7 mg/dL vs. 99.5 mg/dL, \(P < 0.001\)). Linear regression analysis also demonstrated that the PPGE was positively correlated with plasma LDL cholesterol levels (\(\beta\) coefficient: 0.165, \(P < 0.001\)). Postprandial glucose excursion positively correlated with plasma LDL cholesterol levels in individuals with T2DM. Participants with raised PPGE harbored greater LDL cholesterol levels than those with lower postprandial glucose fluctuations. Therefore, postprandial glucose excursion is associated with an atherogenic lipid profile and may be a modifiable risk factor of diabetic CHD.

Introduction

Type 2 diabetes mellitus (T2DM) is a metabolic disorder that induces substantial morbidity in affected patients [1]. Chronic hyperglycemia predisposes patients to microvascular complications including retinopathy, neuropathy, and kidney dysfunction [2]. Importantly, diabetes is also linked to macrovascular diseases such as coronary heart disease (CHD) and peripheral arterial disease [3]. Indeed, cardiovascular disease is a prevalent risk factor of mortality in T2DM [4], and prevention of diabetic CHD has therefore become an integral component of diabetes management guidelines [5,6].
Dyslipidemia in diabetes has several unique features. Insulin resistance increases the flux of free fatty acids to the liver, which subsequently produces an excess of very low-density lipoproteins, leading to elevated plasma triglycerides (TG), reduced high-density lipoprotein (HDL) cholesterol, and oxidized low-density lipoprotein (LDL) cholesterol [7]. Among these lipoprotein fractions, LDL cholesterol contributes to atheroma formation in blood vessels and is an established risk factor of CHD [8]. Therefore, plasma LDL cholesterol is a suitable therapeutic target for the prevention of cardiovascular disease in diabetes, with a level above 100 milligrams per deciliters considered supranormal in diabetic patients [9].

Compared to dyslipidemia, current evidence suggests that plasma glucose plays a less important role in the progression of diabetic CHD. As observed in the United Kingdom Prospective Diabetes Study, for each 4% elevation in serum glycosylated hemoglobin (HbA1c), there was a corresponding 10-fold increase in the incidence of retinopathy but only a twofold rise in CHD incidence [10]. Moreover, correlation studies demonstrated that a considerable proportion of diabetic complications could not be explained by changes in serum HbA1c [11], implying that serum HbA1c alone may not capture the entire spectrum of hyperglycemic complications.

Recently, plasma glucose variability after meals has gained attention as a potential risk factor of cardiovascular complications. In the Whitehall study, the risk of CHD increased in line with plasma glucose levels after an oral glucose tolerance test [12]. Moreover, a European research consortium observed that 2-hour postprandial plasma glucose (PPG) levels closely correlated with cardiovascular risk in T2DM [13]. Therefore, several investigators have proposed that postprandial hyperglycemia may be an HbA1c-independent risk factor of diabetic CHD [14].

Considering the link between postprandial hyperglycemia and cardiovascular risk, the investigators hypothesized that postprandial plasma glucose excursion (PPGE), defined as the difference between 2-hour PPG and fasting plasma glucose (FPG) levels, may influence the plasma lipid profile in a hyperglycemic environment. This study investigates the relationship between PPGE and plasma LDL cholesterol levels in patients with T2DM. Moreover, additional clinical determinants of plasma LDL cholesterol levels in diabetic participants will be examined.

### Materials and methods

#### Study population

Participants in this cross-sectional study were recruited from Changhua Christian Hospital in Taiwan. Candidates visiting the Endocrinology clinic between June 2013 and May 2016 were screened for eligibility. Inclusion criteria to participate in this study were as follows: (1) patients between 21 and 90 years of age, (2) clinically established diagnosis of T2DM according to the criteria of the American Diabetes Association [5], including serum HbA1c level ≥6.5%, FPG ≥ 126 mg/dL, 2-hour plasma glucose levels after 75 gram oral glucose tolerance test ≥ 200 mg/dL or random plasma glucose levels ≥ 200 mg/dL with classic symptoms of diabetes, (3) recipients of metformin monotherapy for diabetes, (4) recipients of at least six months of statin medications, and (5) compliance with blood tests and dietary instructions.

Exclusion criteria were as follows: (1) patients with familial hypercholesterolemia, chronic kidney disease, hypothyroidism, or hemoglobin disorders, (2) recipients of antidiabetic drugs other than metformin, (3) recipients of lipid-lowering therapies other than statin, (4) history of chronic alcoholism, (5) recipients of estrogen replacement therapy, (6) recipients of antidepressants, (7) pregnancy and (8) patients undergoing chemotherapy or radiotherapy for cancer treatment.
Demographic information

Baseline demographic data including age, sex, body weight and height were recorded at the clinic visit. Six months prior to the blood tests, participants received comprehensive medical nutrition therapy according to current guidelines. Specifically, patients were instructed to limit saturated fat to less than 5% of total calories and increase whole grain intake. This adjustment aimed to address the potential confounding effect of dietary habits on plasma lipid levels. Dosage of metformin and statins were adjusted according to patients’ tolerance of medication side effects.

The presence of metabolic syndrome in this study was defined using the U.S. National Cholesterol Education Program criteria, with waist circumference thresholds modified for Asian adults, that requires at least three of the following: (1) waist circumference ≥ 90 cm for males or ≥ 80 cm for females, (2) plasma TG ≥ 150 mg/dl, (3) plasma HDL cholesterol < 40 mg/dL for males or < 50 mg/dL for females, (4) blood pressure ≥ 130/85 mm Hg or treated for hypertension, or (5) fasting plasma glucose 110 mg/dl or treated for diabetes [5].

Laboratory evaluation

Participants underwent a 12-hour fast during which all medications were withheld prior to blood sampling for plasma TG, LDL cholesterol, HDL cholesterol, FPG, serum creatinine, serum alanine transaminase, serum high sensitivity C reactive protein (hs-CRP), and serum HbA1c. Thereafter participants consumed a standard meal, which consisted of 75 grams of carbohydrates, 5 grams of fat and 10 grams of protein, under the supervision of diabetes educators. Two hours after the meal, venous sampling for PPG level was performed. Blood samples were delivered to the central laboratory within one hour of venous sampling and assayed by Beckman Coulter UniCel DxC 800 Synchron Clinical Systems. The analytical precision was within 1.7 mg/dL for HDL cholesterol, within 3.0 mg/dL for LDL cholesterol, within 7.5 mg/dL for TG, and within 2.0 mg/dL for plasma glucose level. The plasma glucose level was quantified by the Hexokinase-UV/NAD end reaction method, whereas plasma HDL cholesterol, LDL cholesterol and TG were measured by the timed endpoint method using a commercial polyanion solution.

Ethics approval

This study was conducted in accordance to the World Medical Association’s Declaration of Helsinki. The protocol was approved by the Institutional Review Board of Changhua Christian Hospital (IRB identifier: Y_108_0013). Participants provided informed consent to take part in the study.

Statistical analysis

Participants were divided into tertiles according to their PPGE, defined as the difference between 2-hour PPG and FPG. Power calculation suggests that a sample size of 105 participants in each tertile is necessary to attain 80% statistical power. The Kolmogorov–Smirnov test was used to verify that clinical variables were normally distributed. All parameters in this study were normally distributed except for plasma triglycerides levels, and the Box-Cox procedure was used to normalize plasma triglyceride levels for statistical analysis. Baseline characteristics including age, gender, mean serum HbA1c, and plasma lipid fractions were compared between PPGE tertiles using one-way analysis of variance with post hoc Tukey’s test. Furthermore, a linear regression analysis was performed to assess the influence of clinical variables on plasma LDL cholesterol levels. Finally, binary logistic regression and sensitivity analysis were
performed to verify the link between PPGE and LDL cholesterol. The Hanley-Mcneil method was used to compare the performance of area under the curve (AUC) of different models with PPGE, without PPGE, with remnant cholesterol, and with ratio of triglycerides and remnant cholesterol. Statistical analysis was performed using Statistical Package for the Social Sciences (version 22.0, SPSS, Chicago, IL), with a two-tailed $P$ value of less than 0.05 interpreted as statistically significant.

**Results**

This study screened 400 patients visiting the Endocrinology clinic for eligibility. Ten individuals were excluded due to chronic kidney disease, seven patients were ineligible due to coexisting hypothyroidism, and four people were excluded for receiving estrogen replacement therapy. The enrolment protocol is illustrated below (Fig 1).

![Enrolment protocol of the study](https://doi.org/10.1371/journal.pone.0258771.g001)
Demographic characteristics of the participants with association between PPGE and plasma lipid profile

The study enrolled 379 participants who were divided into tertiles according to their PPGE. As demonstrated in Table 1, demographic characteristics of the participants including age, sex, serum HbA1c, body mass index, blood pressure, serum creatinine, duration of diabetes, proportions with the metabolic syndrome, waist circumference, and serum alanine transaminase were similar between PPGE tertiles. Moreover, a similar proportion of patients in the PPGE tertiles received either rosvastatin 10 mg, atorvastatin 20 mg, and pravastatin 40 mg, which are equivalent moderate-intensity statins [9]. Patients in each tertile also received similar dose of metformin per day. In the context of plasma glucose levels, participants had comparable FPG levels but considerably different 2-hour PPG levels, which established the basis of this investigation.

Table 1. Demographic features of the participants.

| Parameters                      | Lowest PPGE tertile (n = 126) | Middle PPGE tertile (n = 126) | Highest PPGE tertile (n = 127) | P value |
|---------------------------------|-------------------------------|-------------------------------|-------------------------------|---------|
| Age (years)                     | 62.0 ± 11.6                   | 61.0 ± 12.9                   | 59.7 ± 13.4                   | 0.368   |
| Sex (Female)                    | 74 (58.7%)                    | 58 (46.0%)                    | 69 (54.3%)                    | 0.122   |
| Serum HbA1c (%)                 | 8.12 ± 1.88                   | 8.56 ± 2.21                   | 8.46 ± 2.05                   | 0.201   |
| Diabetes duration (years)       | 5.8 ± 3.0                     | 5.1 ± 3.5                     | 6.0 ± 3.2                     | 0.208   |
| Proportions with metabolic syndrome (number, %) | 19 (15.1%) | 22 (17.4%) | 23 (18.1%) | 0.522 |
| Waist circumference (cm)        | 61.1 ± 11.7                   | 62.6 ± 13.5                   | 61.0 ± 11.9                   | 0.532   |
| BMI (kg/m²)                     | 26.2 ± 4.28                   | 26.3 ± 4.74                   | 26.0 ± 4.72                   | 0.889   |
| SBP (mm Hg)                     | 131 ± 16.4                    | 131 ± 15.8                    | 133 ± 16.8                    | 0.628   |
| DBP (mm Hg)                     | 78.3 ± 11.6                   | 79.6 ± 10.1                   | 78.6 ± 10.7                   | 0.596   |
| Serum creatinine (mg/dL)        | 0.826 ± 0.233                 | 0.876 ± 0.259                 | 0.839 ± 0.224                 | 0.232   |
| Serum ALT (U/L)                 | 33.9 ± 21.7                   | 35.8 ± 26.0                   | 35.7 ± 27.9                   | 0.788   |
| FPG (mg/dL)                     | 122 ± 22.0                    | 128 ± 32.1                    | 130 ± 34.3                    | 0.086   |
| 2-hour PPG (mg/dL)              | 134 ± 22.7                    | 169 ± 35.8                    | 242 ± 63.7                    | <0.001  |
| PPGE (mg/dL)                    | 11.8 ± 6.04                   | 40.9 ± 11.1*                  | 111.8±55.3*<0.001            |         |
| Use of medications              |                               |                               |                               |         |
| Rosuvastatin 10 mg              | 48 (38.1%)                    | 42 (33.3%)                    | 37 (29.1%)                    | 0.578   |
| Atorvastatin 20 mg              | 52 (41.3%)                    | 60 (47.6%)                    | 61 (48.0%)                    | 0.506   |
| Pravastatin 40 mg               | 26 (20.6%)                    | 24 (19.0%)                    | 29 (22.8%)                    | 0.888   |
| Metformin dose (mg per day)     | 1310 ± 468                    | 1313 ± 472                    | 1374 ± 504                    | 0.491   |
| Plasma total cholesterol (mg/dL)| 175.8 ± 37.9                  | 189.5 ± 39.6*                 | 202.7 ± 36.0<0.001           |         |
| Plasma TG (mg/dL)               | 156.6 ± 97.5                  | 149.1 ± 71.4                  | 142.9 ± 72.9                  | 0.408   |
| Plasma HDL-C (mg/dL)            | 45.0 ± 11.66                  | 44.9 ± 11.3                   | 47.8 ± 12.3                   | 0.080   |
| Plasma LDL-C (mg/dL)            | 99.5 ± 29.4                   | 114.5±33.4*                  | 126.7±28.2<0.001             |         |
| Plasma non-HDL-C (mg/dL)        | 130.8 ± 35.5                  | 144.5 ± 37.3*                 | 155.1 ± 33.4<0.001           | <0.001  |
| Plasma remnant cholesterol (mg/dL) | 31.2 ± 19.5                  | 29.6 ± 14.2                   | 28.8 ± 14.7                   | 0.462   |
| Serum hs-CRP (mg/dL)            | 0.2 ± 0.13                    | 0.25 ± 0.19                   | 0.28 ± 0.2*                   | 0.0022  |

Data are expressed as means with standard deviation of the mean for continuous variables and number (%) for categorical variables. Variables are compared between groups using one-way analysis of variance for continuous variables and Pearson’s χ²-test for categorical variables. Postprandial plasma glucose excursion is defined as the difference between 2-hour postprandial and fasting plasma glucose levels. ALT: Alanine aminotransferase, BMI: Body mass index, FPG: Fasting plasma glucose, PPGE: Postprandial plasma glucose excursion, mg/dL: Milligrams per deciliter, mm Hg: Millimeters of mercury, kg: Kilograms, m: Meters, mg: Milligrams, hs-CRP: High sensitivity C reactive protein, TG: Triglycerides, HDL-C: High density lipoprotein cholesterol, LDL-C: Low density lipoprotein cholesterol.

https://doi.org/10.1371/journal.pone.0258771.t001

PLOS ONE | https://doi.org/10.1371/journal.pone.0258771 October 20, 2021 5 / 10
As established in the study design, mean PPGE of the highest tertile was significantly greater than that of the lowest tertile (112 mg/dL vs. 11.8 mg/dL, \( P < 0.001 \)). Participants in both the highest and lowest PPGE tertiles had similar levels of plasma TG (142.9 mg/dL vs. 156.6 mg/dL, \( P = 0.408 \)) and HDL cholesterol (47.8 mg/dL vs. 45 mg/dL, \( P = 0.08 \)). However, patients in the highest PPGE tertile had substantially greater levels of plasma LDL cholesterol (126.7 mg/dL vs. 99.5 mg/dL, \( P < 0.001 \)), total cholesterol (202.7 mg/dL vs. 175.8 mg/dL, \( P < 0.001 \)), as well as non-HDL cholesterol (155.1 mg/dL vs. 130.8 mg/dL, \( P < 0.001 \)) than those in the lowest PPGE tertile. Moreover, patients with the highest PPGE harbored higher serum hs-CRP levels relative to those in the lowest PPGE tertile (0.28 mg/dL vs. 0.2 mg/dL, \( P = 0.0022 \)). These findings are also summarized in Table 1.

**Clinical determinants of plasma low-density lipoprotein cholesterol levels**

As shown in Table 2, linear regression analysis demonstrated that the PPGE was positively correlated with plasma LDL cholesterol levels (\( \beta \) coefficient: 0.165, \( P < 0.001 \)). In contrast, other clinical parameters did not demonstrate an association with plasma LDL cholesterol levels in this study.

**Binary logistic regression and sensitivity analysis of plasma low-density lipoprotein cholesterol prediction**

Binary logistic regression analysis verified an independent link between PPGE and LDL cholesterol levels (Coefficient: 0.125, \( P < 0.001 \)). Sensitivity analysis with receiver operating characteristic curve, as shown in Fig 2A, demonstrated that PPGE is correlated with LDL cholesterol levels with an AUC of 0.744. In contrast, sensitivity analysis showed an AUC of 0.68 for the model without PPGE and an AUC of 0.62 for the model with remnant cholesterol, as shown in Fig 2B and 2C respectively. A model that stratifies participants by ratio of triglycerides and remnant cholesterol levels demonstrates an AUC of 0.64, as shown in Fig 2D.

Application of the Hanley-Mcneil method showed a difference in AUC between models with PPGE and without PPGE (\( \Delta \) AUC: 0.06, standard error (SE): 0.036, \( P = 0.03 \)), with PPGE and remnant cholesterol (\( \Delta \) AUC: 0.12, SE: 0.04, \( P = 0.001 \)), and with PPGE and ratio of triglycerides and remnant cholesterol (\( \Delta \) AUC: 0.1, SE: 0.038, \( P = 0.0035 \)).

**Table 2. Linear regression analysis of parameters associated with plasma low-density lipoprotein cholesterol concentration.**

| Parameters                  | \( \beta \) coefficient | \( P \) value |
|-----------------------------|--------------------------|---------------|
| Age (years)                 | -0.21                    | 0.12          |
| BMI (kg/m\(^2\))           | 0.62                     | 0.1           |
| Serum creatinine (mg/dL)    | -0.24                    | 0.45          |
| SBP (mm Hg)                 | -0.1                     | 0.3           |
| Diabetes duration (years)   | 0.68                     | 0.17          |
| Serum ALT (U/L)             | -0.11                    | 0.1           |
| FPG (mg/dL)                 | -0.08                    | 0.15          |
| Serum HbA1c                 | 0.52                     | 0.52          |
| PPGE (mg/dL)                | 0.16                     | < 0.001       |

Postprandial plasma glucose excursion is defined as the difference between 2-hour postprandial and fasting plasma glucose levels. BMI: Body mass index, FPG: Fasting plasma glucose, Alt: Alanine aminotransferase, HbA\(_{1c}\): Glycosylated hemoglobin A\(_{1c}\), PPGE: Postprandial plasma glucose excursion, mg/dL: Milligrams per deciliter, mm Hg: Millimeters of mercury, kg: Kilograms, m: Meters, mg: Milligrams.

https://doi.org/10.1371/journal.pone.0258771.t002
Discussion

This study observed a positive correlation between postprandial glucose excursion and LDL cholesterol levels in patients with T2DM. Participants with higher PPGE had greater plasma LDL cholesterol levels than patients with lower postprandial glucose fluctuations. Moreover, linear regression analysis verified that postprandial hyperglycemia significantly correlated with plasma LDL cholesterol levels. Sensitivity analysis demonstrates that PPGE has an appreciable correlation with LDL cholesterol levels in diabetic participants. Nonetheless, further studies are necessary to confirm this association in different patient populations.

Postprandial hyperglycemia may promote the accumulation of atherogenic LDL cholesterol through several pathways. Transient hyperglycemia accelerates the glycation of LDL cholesterol particles, which impairs their receptor-mediated catabolism by the liver [15]. Glycation also prolongs the half-life of LDL cholesterol and enhances its oxidation to form atherogenic metabolites [16]. Recent studies also demonstrated that transient hyperglycemia induces epigenetic changes in cholesterol receptors of the liver [17], leading to dysfunctional lipid catabolism [18]. Moreover, postprandial hyperglycemia promotes the generation of reactive oxygen species that impair the clearance of circulating lipid metabolites [19], in addition to microribonucleic acid particles that disrupt the endothelial function of coronary arteries [20,21]. Recent evidence also suggests that transient hyperglycemia disrupts coronary flow reserve in patients with T2DM [22,23].

The observation in this study that PPGE positively correlated with plasma LDL cholesterol levels has clinical implications. Antidiabetic medications that target postprandial hyperglycemia such as alpha-glucosidase inhibitors (AGI) and glucagon-like peptide 1 (GLP-1) agonists can lower cardiovascular event rates in T2DM, partly through reduction of plasma LDL cholesterol levels [24,25]. In terms of CHD prevention, therefore, patients with raised PPGE may benefit from antidiabetic medications that target postprandial glucose variability, which may also reduce plasma LDL cholesterol levels. In addition to pharmacologic interventions, medical nutrition therapy has been shown to alleviate postprandial hyperglycemia [26], which

Fig 2. Sensitivity analysis with receiver operating characteristics curve. (A) Model with postprandial glucose excursion. (B) Model without postprandial glucose excursion. (C) Model with plasma remnant cholesterol. (D) Model with stratification by ratio of triglycerides and remnant cholesterol.

https://doi.org/10.1371/journal.pone.0258771.g002
potentially attenuates the atherogenic lipid profile in individuals with raised PPGE. At-risk individuals may also benefit from regular physical exercise to mitigate postprandial glucose fluctuations [27]. Moreover, this study demonstrated that participants with similar levels of serum HbA1c may nonetheless have different PPGE. This finding concurs with the NHANES III study, which has shown that in diabetic patients with similar levels of serum HbA1c, nearly 40% demonstrated substantial postprandial hyperglycemia while the remainder had normal postprandial glucose levels [28].

The strength of this study includes a sizeable patient population enrolled from our endocrinology clinic, which renders the findings applicable to general practice. Participants withheld all medications during the 12-hour fast before blood tests to reduce potential confounding effects of these medications on plasma glucose levels and lipid profile. Moreover, certified diabetes educators supervised the study to avert potential errors in plasma glucose sampling and provided comprehensive medical nutrition therapy to participants to ensure similar levels of dietary lipid intake.

Nonetheless, this study has several limitations. Firstly, PPGE was assessed by consuming a standard meal and may not reflect daily glycemic excursion. The use of continuous glucose monitoring may more accurately reflect PPGE. Moreover, additional factors that influence postprandial glucose levels, such as the metabolic syndrome or insulin resistance, were unaccounted for in the study protocol. Importantly, secretory reserve of the pancreas can modify postprandial glucose levels but insulin levels were not quantified in the study. Furthermore, since postprandial glucose determination is influenced by concomitant hyperlipidemia, plasma lipid levels at the time of laboratory testing may interfere with the accuracy of PPGE quantification. Although postprandial lipid profile has been shown to correlate with cardiovascular risk [29], many clinical laboratories, including the one at the investigators’ institution, require lipid sampling under fasting condition to avoid postprandial variability in plasma TG [30]. Therefore, the absence of postprandial lipid profile in this study constitutes an additional limitation. Importantly, since participants in this study received statins in accordance with diabetes management guidelines [5], the findings in the study are applicable only to diabetic patients treated with statins.

Conclusions
In conclusion, postprandial glucose excursion positively correlated with plasma LDL cholesterol levels in individuals with T2DM. Participants with raised PPGE harbored greater LDL cholesterol levels than those with lower postprandial glucose fluctuations. Therefore, postprandial glucose excursion is associated with an atherogenic lipid profile and may be a modifiable risk factor of diabetic CHD.

Supporting information
S1 File. Research dataset for the study.
(XLSX)

Acknowledgments
The authors would like to thank diabetes educators at Changhua Christian Hospital for supervising the study.

Author Contributions
Conceptualization: Chia-Hung Kao.
Data curation: Chia-Hung Kao.
Formal analysis: Chia-Hung Kao.
Funding acquisition: Chia-Hung Kao.
Investigation: Po-Chung Cheng, Chia-Hung Kao.
Methodology: Chia-Hung Kao.
Project administration: Chia-Hung Kao.
Resources: Chia-Hung Kao.
Software: Po-Chung Cheng.
Supervision: Chia-Hung Kao.
Writing – original draft: Po-Chung Cheng.
Writing – review & editing: Chia-Hung Kao.

References

1. Centers for Disease Control and Prevention. National diabetes statistics report, 2020. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services (2020).

2. Barrett EJ, Liu Z, Khamaisi M, King GL, Klein R, Klein BEK, et al. Diabetic Microvascular Disease: An Endocrine Society Scientific Statement. J Clin Endocrinol Metab. 2017; 102(12):4343–4410. https://doi.org/10.1210/jc.2017-01922 PMID: 29126250

3. Kosiborod M, Gomes MB, Nicolini A, Pocock S, Rathmann W, Shestakova MV, et al. Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). Cardiovasc Diabetol. 2018; 17(1):150. https://doi.org/10.1186/s12933-018-0787-8 PMID: 30468089

4. Carnethon MR, Biggs ML, Barzilay J, Kuller LH, Mozaffarian D, Mukamal K, et al. Diabetes and coronary heart disease as risk factors for mortality in older adults. Am J Med. 2010; 123(6):556.e1–9. https://doi.org/10.1016/j.amjmed.2009.11.023 PMID: 20569763

5. American Diabetes Association. Standards of medical care in diabetes-2020. Diabetes Care. 2020; 43, S1–S2. https://doi.org/10.1183/0300241X.00101920 PMID: 31862741

6. International Diabetes Federation. IDF Diabetes Atlas, 8th edn., Brussels, Belgium: International Diabetes Federation (2017).

7. Hirano T. Pathophysiology of Diabetic Dyslipidemia. J Atheroscler Thromb. 2018; 25(9):771–782. https://doi.org/10.5551/jat.RV17023 PMID: 29998913

8. Imano H, Noda H, Kitamura A, Sato S, Kiyama M, Sankai T, et al. Low-density lipoprotein cholesterol and risk of coronary heart disease among Japanese men and women: the Circulatory Risk in Communities Study (CIRCS). Prev Med. 2011; 52(5):381–6. https://doi.org/10.1016/j.ypmed.2011.02.019 PMID: 21371493

9. Grundy SM, Stone NJ, Bailey AL, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Jun 25; 73(24):3169–3209. https://doi.org/10.1016/j.jacc.2018.11.002 PMID: 30423391

10. King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999; 48(5):643–648. https://doi.org/10.1046/j.1365-2125.1999.00092.x PMID: 10394464

11. Cohen RM, Lindsell CJ. When the blood glucose and the HbA1c don’t match: turning uncertainty into opportunity. Diabetes Care. 2012; 35(12):2421–2423. https://doi.org/10.2337/dc12-1479 PMID: 23173128

12. Fuller JH, McCartney P, Jarrett RJ, Keen H, Rose G, Shipley MJ et al. Hyperglycaemia and coronary heart disease: the Whitehall study. J Chronic Dis. 1979; 32(11–12):721–8. https://doi.org/10.1016/0021-9681(79)90051-1 PMID: 511967

13. DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch. Intern. Med. 2001; 161:397–405. https://doi.org/10.1001/archinte.161.3.397 PMID: 11176766
14. Jiang J, Zhao L, Lin L, Gui M, Aleteng Q, Wu B, et al. Postprandial Blood Glucose Outweighs Fasting Blood Glucose and HbA1c in screening Coronary Heart Disease. Sci Rep. 2017; 7(1):14212. https://doi.org/10.1038/s41598-017-14152-y PMID: 29079813

15. Younis N, Sharma R, Soran H, Charlton-Menys V, Elseweidy M, Durrington PN. Glycation as an athero-genic modification of LDL. Curr Opin Lipidol. 2008; 19(4):378–84. https://doi.org/10.1097/MOL.0b013e328306a057 PMID: 18607185

16. Zimmermann R, Panzenböck U, Wintersperger A, Levak-Frank S, Graier W, Glatter O, et al. Lipoprotein lipase mediates the uptake of glycated LDL in fibroblasts, endothelial cells, and macrophages. Diabetes. 2001; 50(7):1643–53. https://doi.org/10.2337/diabetes.50.7.1643 PMID: 11423487

17. Villeneuve LM, Natarajan R. Epigenetics of diabetic complications. Expert Rev. Endocrinol. Metab. 2010; 5: 137–148. https://doi.org/10.1586/eem.09.54 PMID: 24077653

18. Nilsson E, Matte A, Perfiliev A, de Mello VD, Kajihara N, Sonoda K, et al. Epigenetic Alterations in human liver from subjects with type 2 diabetes in parallel with reduced folate levels. J Clin Endocrinol Metab. 2015; 100(11):E1491–501. https://doi.org/10.1210/jc.2015-3204 PMID: 26418287

19. Sada K, Nishikawa T, Kukidome D, Yoshinaga T, Kajihara N, Sonoda K, et al. Hyperglycemia Induces Cellular Hypoxia through Production of Mitochondrial ROS Followed by Suppression of Aquaporin-1. PLoS One. 2016; 11(7):e0158619. https://doi.org/10.1371/journal.pone.0158619 PMID: 27383386

20. Melak T, Baynes HW. Circulating microRNAs as possible biomarkers for coronary artery disease: a narrative review. EJIFCC. 2019; 30:179–194. PMID: 31263392

21. Zhang X, Xu X, Jiao X, Wu J, Zhou S, Lv X. The effects of glucose fluctuation on the severity of coronary artery disease in type 2 diabetes mellitus. J Diabetes Res. 2013; 2013:576916. https://doi.org/10.1155/2013/576916 PMID: 23963667

22. Ikeda H, Uzui H, Morishita T, Fukuda Y, Sato T, Ishida K, et al. Effect of postprandial hyperglycaemia on coronary flow reserve in patients with impaired glucose tolerance and type 2 diabetes mellitus. Diab Vasc Dis Res. 2015; 12(6):405–10. https://doi.org/10.1177/1479164115597866 PMID: 26297527

23. Node K, Inoue T. Postprandial hyperglycemia as an etiological factor in vascular failure. Cardiovasc Diabetol. 2009; 8:23. https://doi.org/10.1186/1475-2840-8-23 PMID: 19402896

24. Standl E, Theodorakis MJ, Erbach M, Schnell O, Tuomilehto J. On the potential of acarbose to reduce cardiovascular disease. Cardiovasc Diabetol. 2014; 13:81. https://doi.org/10.1186/1475-2840-13-81 PMID: 24742256

25. Del Olmo-García MI, Merino-Torres JF. GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes. J Diabetes Res. 2018; 2018:4020492. https://doi.org/10.1155/2018/4020492 PMID: 29805980

26. Evert AB, Boucher JL, Cypress M, Dunbar SA, Franz MJ, Mayer-Davis EJ, et al. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care. 2014 Jan; 37 Suppl 1: S120–43. https://doi.org/10.2337/dc14-S120 PMID: 24357208.

27. Solomon TPJ, Eves FF, Laye MJ. Targeting Postprandial Hyperglycemia With Physical Activity May Reduce Cardiovascular Disease Risk. But What Should We Do, and When Is the Right Time to Move?. Front Cardiovasc Med. 2018; 5:99. https://doi.org/10.3389/fcvm.2018.00099 PMID: 30073171

28. Erlinger TP, Brancati FL. Postchallenge hyperglycemia in a national sample of U.S. adults with type 2 diabetes. Diabetes Care. 2001; 24(10):1734–8. https://doi.org/10.2337/diacare.24.10.1734 PMID: 11574434

29. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007; 298(3):309–316. https://doi.org/10.1001/jama.298.3.309 PMID: 17635891

30. Higgins V, Adell K. Postprandial Dyslipidemia: Pathophysiology and Cardiovascular Disease Risk Assessment. EJIFCC. 2017; 28(3):168–184. PMID: 29075168